DelveInsight's "Geographic Atrophy (GA) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Geographic Atrophy (GA) , historical and forecasted epidemiology as well as the Geographic Atrophy (GA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Geographic Atrophy (GA) market report provides current treatment practices, emerging drugs, Geographic Atrophy (GA) market share of the individual therapies, current and forecasted Geographic Atrophy (GA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Geographic Atrophy (GA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.
GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.
GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or ‘blind spots’. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors.
Diagnosis
The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.
Treatment
Currently, there are no approved treatments present for GA. The AREDS study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene and zinc could significantly reduce the risk of progressing to advanced AMD and sometimes low visual aids and counseling is also helpful. Several therapies which reached in advanced stage of development are already failed, however currently several therapies are in the pipeline to prevent the progression of GA.
The Geographic Atrophy (GA) epidemiology division provide insights about historical and current Geographic Atrophy (GA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The total prevalent cases of GA in the 7MM were found to be 2,726,453 in 2017 which is expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted GA epidemiology [segmented as Total Prevalent Cases of GA, Total Diagnosed Cases of GA, Total Diagnosed cases of GA by Age Distribution, Total Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of GA] scenario of GA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Country Wise- Geographic Atrophy (GA) Epidemiology
The epidemiology segment also provides the Geographic Atrophy (GA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Drug chapter segment of the Geographic Atrophy (GA) report encloses the detailed analysis of Geographic Atrophy (GA) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Geographic Atrophy (GA) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Pegcetacoplan (APL-2): Apellis Pharmaceuticals
Pegcetacoplan (formerly known as APL-2), is under development by Apellis Pharmaceuticals. It is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.
Currently two phase III trial is ongoing for GA secondary to age-related macular degeneration (AMD). The Phase III program in GA consists of two 600-patient prospective, multicenter, randomized, double-masked, sham-injection controlled trials to assess the efficacy and safety of multiple intravitreal injections of pegcetacoplan in patients with GA, with the goal of enrolling a total of 1,200 patients across approximately 200 sites worldwide. Company refers to these trials as the DERBY and OAKS trials. Company dosed the first patient in Phase III trials in September 2018. It is expected that both trials will be fully enrolled by the end of the first half of 2020 and anticipated announcement of data from these trials will be in mid-2021.
In July 2018, the US FDA granted fast track designation to Pegcetacoplan for GA.
In November 2014, Apellis Pharmaceuticals entered into an agreement to acquire Potentia Pharmaceuticals. As part of the acquisition agreement, Apellis obtained the necessary intellectual property rights to develop its complement inhibitor drug compound (APL-2) in ophthalmology.
Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)
Zimura also known as avacincaptad pegol, is under development by Iveric Bio. It is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD.
The drug is currently in Phase IIb trial for the treatment of patients with GA Secondary to Dry AMD. However, in January 2020, the Company announced the design of second Phase III clinical trial of Zimura in geographic atrophy secondary to AMD, ISEE2008. In March 18, 2020, the Company announced that due to the COVID-19 pandemic, it had decided to delay the initiation of patient enrollment in the ISEE2008 trial, which was otherwise on track to begin in March 2020. The Company continues to monitor the situation closely in the United States and abroad to determine when enrollment should begin.
The Company expected topline 18-month data from its first Phase III clinical trial evaluating Zimura for the treatment of GA secondary to AMD, OPH2003, will be available by the end of the second quarter of 2020. The primary purpose of the 18-month time point is to gather additional safety data.
In April 2020, the US FDA granted Fast Track designation to Zimura for the treatment of GA secondary to AMD.
ALK-001: Alkeus Pharmaceuticals
Alkeus' drug candidate, ALK-001, is a once-a-day oral drug candidate currently being tested for the treatment of GA, which offers a chemically modified version of the vitamin that is designed to reduce the formation of those toxic clumps. ALK-001 works by replacing the C20 hydrogen atoms of vitamin A with deuterium atoms which makes cleavage of the carbon-hydrogen bond more difficult, thereby reduces Vitamin A dimerization and lipofuscin.
The company has completed a phase I clinical study (NCT02230228) which was conducted to assess the safety and pharmacokinetics of ALK-001 in healthy volunteer. At present, a Phase III (NCT03845582; Recruiting) multicenter, randomized, double-masked, parallel-group, placebo-controlled study is ongoing to investigate the safety, pharmacokinetics, tolerability, and efficacy of ALK-001 in GA Secondary to Age-related Macular Degeneration.
In January 2011, Alkeus Pharmaceuticals and Columbia University entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye.
HMR59 (AAVCAGsCD59): Hemera Biosciences
HMR59 (HMR-1001; AAVCAGsCD59) is Hemera’s one-time gene therapy that works by causing retina cells to continuously produce a soluble protein called CD59 (sCD59) that blocks the final step of the complement cascade. This drug is currently being evaluated in the US FDA approved clinical trials to treat both dry and wet AMD. Macular degeneration is felt to be caused by an over activity of an inflammation cascade called complement.
In preclinical testing, AAVCAGsCD59 injected in the vitreous of mice 14 days prior to laser CNV reduced CNV formation by ~60% and MAC formation by ~70%. Hemera Biosciences’s expecting to initiate a Phase II (NCT04358471; Not yet recruiting) multi-center trial in June 30, 2020, evaluating intravitreal AAVCAGsCD59 compared to sham injection for the treatment of advanced dry AMD with GA. The one-year key findings of a Phase I dose-escalation trial of HMR59 in dry AMD have shown about a 25% reduction in the growth rate of GA.
Products detail and others products of pipeline in the report…
At present, the therapeutic landscape of GA is devoid of any approved treatment, and to manage this indication, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of GA is poorly understood. Although correlative evidence for complement, inflammation, and GA pathology has been found in human tissues, a causative role for complement, or for inflammation in general, can be demonstrated only in appropriate preclinical models of GA.
The current standard of Care is observation, and besides high doses of antioxidant vitamin, zinc supplements are found to produce a beneficial effect in slowing the progression of d-AMD. In the absence of any treatment and because of a poor correlation between BCVA and GA lesions or progression, a multimodal imaging approach is necessary to better follow up GA patients.
Several companies tried to develop a drug for this condition, but failed. One such example is Lampalizumab (Genentech/Roche). This drug blocks a region on factor D that is an important binding site for factor B. As a result, factor B cannot be cleaved therefore inhibits the alternate complement pathway.
In September 2017, press releases from Roche and Genentech announced that two phase III clinical trials of lampalizumab (Spectri and Chroma), failed to meet their primary end point of reducing mean change in GA lesion area after 48 weeks when compared with sham treatment.
At present several pharmaceutical companies are working for the development of novel approach to treat this condition. Key players like Apellis Pharmaceuticals (Pegcetacoplan; APL-2), Alkeus Pharmaceuticals (ALK-001), Iveric bio (formerly Ophthotech Corporation; Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals./ Roche (IONIS-FB-LRx), Hemera Biosciences (HMR59), Allegro Ophthalmics(Risuteganib), Stealth BioTherapeutics (Elamipretide), Janssen Research & Development (Palucorcel; CNTO 2476), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences (OpRegen), Gyroscope Therapeutics (GT005), and others.
The GA market size in the 7MM is expected to change during the study period 2017–2030.The therapeutic market of GA in the seven major markets was USD 276 million in 2017 which is expected to increase during study period (2017–2030). According to the estimates, the highest market size of GA is found in the United States followed by the UK and France. In case of clinical trials of emerging therapies, no active companies in this space currently focusing on Japan and also no visibility around the launch scenarios in Japan hence emerging therapies launch is not considered in Japan.
The United States Market Outlook
In 2017, the total market size of GA therapies was USD 181 million in the United States which is expected to increase in the study period (2017–2030).
EU-5 Countries: Market Outlook
In 2017, the total market size of GA therapies was USD 83 million in the EU-5 countries which is expected to increase in the study period (2017–2030).
Japan Market Outlook
The total market size of GA therapies in Japan was USD 12 million in 2017.
HMR59 (Gene Therapy) expected to generate highest market size owing to one time treatment approach, expected premium pricing and impressive early stage efficacy data.
Furthermore, there are no significant differences seen in the available efficacy results of APL-2 and Zimura; but Zimura owing to better safety profile expected to have slight edge over APL-2. So, Zimura is expected to generate second highest revenue in the total GA market.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Geographic Atrophy (GA) key players involved in developing targeted therapeutics.
Pipeline Development Activities
The drugs which are in pipeline include:
To keep up with current market trends, we take KOLs and SME's opinion working in Geographic Atrophy (GA) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Geographic Atrophy (GA) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Prof. Medical Director, Department of Ophthalmology, University of Bonn, Germany Views:
We perform Competitive and Market Intelligence analysis of the Geographic Atrophy (GA) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Geographic Atrophy (GA)
3. KOL Views
4. SWOT Analysis of Geographic Atrophy (GA)
5. Geographic Atrophy: Market Overview at a Glance
6. Geographic Atrophy: Disease Background and Overview
6.1. Age-related Macular Degeneration (AMD)
6.1.1. Estimating Risk of AMD Progression
6.1.2. Symptoms of AMD
6.1.3. Stages of AMD
6.2. Geographic Atrophy (GA)
6.2.1. Signs and symptoms of GA
6.2.2. Risk Factors of GA
6.2.3. Prognostic factors for GA
6.2.4. Disease Progression of GA
6.2.5. Pathophysiology of GA
7. Diagnosis/Imaging of GA
8. Epidemiology and Patient Population
8.1. Epidemiology Key Findings
8.2. Assumptions and Rationale: 7MM
8.3. Epidemiology Scenario: 7MM
8.3.1. Total Prevalent Cases of Geographic Atrophy in the 7MM
8.3.2. Total Diagnosed cases of Geographic Atrophy in the 7MM
8.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM
8.3.4. Total Geographic Atrophy Cases by Visual Impairment in the 7MM
8.3.5. Treated cases of Geographic Atrophy in the 7MM
9. The United States Epidemiology
9.1. Total Prevalent Cases of Geographic Atrophy in the United States
9.2. Total Diagnosed cases of Geographic Atrophy in the United States
9.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States
9.4. Total Geographic Atrophy Cases by Visual impairment in the United States
9.5. Treated cases of Geographic Atrophy in the United States
10. EU-5 Epidemiology
10.1. Germany
10.1.1. Total Prevalent Cases of Geographic Atrophy in Germany
10.1.2. Total Diagnosed cases of Geographic Atrophy in Germany
10.1.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany
10.1.4. Total Geographic Atrophy Cases by Visual Impairment in Germany
10.1.5. Treated cases of Geographic Atrophy in Germany
10.2. France
10.2.1. Total Prevalent Cases of Geographic Atrophy in France
10.2.2. Total Diagnosed cases of Geographic Atrophy in France
10.2.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in France
10.2.4. Total Geographic Atrophy Cases by Visual Impairment in France
10.2.5. Treated cases of Geographic Atrophy in France
10.3. Italy
10.3.1. Total Prevalent Cases of Geographic Atrophy in Italy
10.3.2. Total Diagnosed cases of Geographic Atrophy in Italy
10.3.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy
10.3.4. Total Geographic Atrophy Cases by Visual Impairment in Italy
10.3.5. Treated cases of Geographic Atrophy in Italy
10.4. Spain
10.4.1. Total Prevalent Cases of Geographic Atrophy in Spain
10.4.2. Total Diagnosed cases of Geographic Atrophy in Spain
10.4.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain
10.4.4. Total Geographic Atrophy Cases by Visual Impairment in Spain
10.4.5. Treated cases of Geographic Atrophy in Spain
10.5. The United Kingdom
10.5.1. Total Prevalent Cases of Geographic Atrophy in the United Kingdom
10.5.2. Total Diagnosed cases of Geographic Atrophy in the United Kingdom
10.5.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom
10.5.4. Total Geographic Atrophy Cases by Visual Impairment in the United Kingdom
10.5.5. Treated cases of Geographic Atrophy in the United Kingdom
11. Japan Epidemiology
11.1. Total Prevalent Cases of Geographic Atrophy in Japan
11.2. Total Diagnosed cases of Geographic Atrophy in Japan
11.3. Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan
11.4. Total Geographic Atrophy Cases by Visual Impairment in Japan
11.5. Treated cases of Geographic Atrophy in Japan
12. Treatment of GA
12.1. Treatment Algorithm AMD
12.2. Current Treatment
12.3. Ongoing Research to Evaluate New Treatment Options
13. Unmet Needs
14. Patient Journey of GA
15. Key Endpoints in Geographic Atrophy (GA) Clinical Trials
16. Emerging Therapies
16.1. Key Cross
16.2. Pegcetacoplan (APL-2): Apellis Pharmaceuticals
16.2.1. Product Description
16.2.2. Other Developmental Activities
16.2.3. Clinical Development
16.2.4. Safety and Efficacy
16.3. Zimura (avacincaptad pegol): Iveric Bio (formerly Ophthotech Corporation)
16.3.1. Product Description
16.3.2. Other Developmental Activities
16.3.3. Clinical Development
16.3.4. Safety and Efficacy
16.4. ALK-001: Alkeus Pharmaceuticals
16.4.1. Product Description
16.4.2. Other Developmental Activities
16.4.3. Clinical Development
16.5. HMR59 (AAVCAGsCD59): Hemera Biosciences
16.5.1. Product Description
16.5.2. Other Developmental Activities
16.5.3. Clinical Development
16.5.4. Safety and Efficacy
16.6. Risuteganib: Allegro Ophthalmics
16.6.1. Product Description
16.6.2. Other Developmental Activities
16.6.3. Clinical Development
16.6.4. Safety and Efficacy
16.7. Elamipretide: Stealth BioTherapeutics
16.7.1. Product Description
16.7.2. Other Developmental Activities
16.7.3. Clinical Development
16.7.4. Safety and Efficacy
16.8. GT005: Gyroscope Therapeutics
16.8.1. Product Description
16.8.2. Other Developmental Activities
16.8.3. Clinical Development
16.9. CPCB-RPE1: Regenerative Patch Technologies
16.9.1. Product Description
16.9.2. Other Developmental Activities
16.9.3. Clinical Development
16.9.4. Safety and Efficacy
16.10. RO7171009 (RG6147): Roche (Genentech)
16.10.1. Product Description
16.10.2. Other Developmental Activities
16.10.3. Clinical Development
16.11. IONIS-FB-LRx: Ionis Pharmaceuticals/Roche
16.11.1. Product Description
16.11.2. Other Developmental Activities
16.11.3. Clinical Development
16.12. OpRegen: CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
16.12.1. Product Description
16.12.2. Other Developmental Activities
16.12.3. Clinical Development
16.12.4. Safety and Efficacy
16.13. Palucorcel (CNTO 2476): Janssen Research & Development
16.13.1. Product Description
16.13.2. Other Developmental Activities
16.13.3. Clinical Development
16.13.4. Safety and Efficacy
17. Conjoint Analysis of Geographic Atrophy (GA)
18. Geographic Atrophy (GA): Seven Major Market Analysis
18.1. Key Findings
18.2. Market Outlook: 7MM
19. 7MM Market Size
19.1. Total Market Size of Geographic Atrophy in the 7MM
19.2. Total Market size of Geographic Atrophy by Therapies in the 7MM
19.3. United States Market Size
19.3.1. Total Market size of Geographic Atrophy in the United States
19.4. EU-5 Market Size
19.4.1. Germany Market Size
19.4.2. France Market Size
19.4.3. Italy Market Size
19.4.4. Spain Market Size
19.4.5. United Kingdom Market Size
19.5. Japan Market Size
19.5.1. Total Market size of Geographic Atrophy in Japan
20. Market Access and Reimbursement of Geographic Atrophy (GA) Therapies
20.1. Issues Associated with Access and Reimbursement of Gene Therapies
20.2. Access and Reimbursement of Wet AMD Therapies
21. Market Drivers of GA
22. Market Barriers of GA
23. Appendix
23.1. Bibliography
23.2. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
List of Tables:
Table 1: Summary of GA Market, Epidemiology, and Key Events (2017–2030)
Table 2: The four-stage classification of AMD from the Age-Related Eye Disease Study (AREDS)
Table 3: AREDS Risk Factor Scoring System
Table 4: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017–2030)
Table 5: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017–2030)
Table 6: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017–2030)
Table 7: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017–2030)
Table 8: Total Treated cases of Geographic Atrophy in the 7MM (2017–2030)
Table 9: Total Prevalent Cases of Geographic Atrophy in the United States (2017–2030)
Table 10: Total Diagnosed cases of Geographic Atrophy in the United States (2017–2030)
Table 11: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017–2030)
Table 12: Total Geographic Atrophy Cases by Visual Impairment in the US (2017–2030)
Table 13: Total Treated cases of Geographic Atrophy in the US (2017–2030)
Table 14: Total Prevalent Cases of Geographic Atrophy in Germany (2017–2030)
Table 15: Total Diagnosed cases of Geographic Atrophy in Germany (2017–2030)
Table 16: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017–2030)
Table 17: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017–2030)
Table 18: Total Treated cases of Geographic Atrophy in Germany (2017–2030)
Table 19: Total Prevalent Cases of Geographic Atrophy in France (2017–2030)
Table 20: Total Diagnosed cases of Geographic Atrophy in France (2017–2030)
Table 21: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017–2030)
Table 22: Total Geographic Atrophy Cases by Visual Impairment in France (2017–2030)
Table 23: Total Treated cases of Geographic Atrophy inFrance (2017–2030)
Table 24: Total Prevalent Cases of Geographic Atrophy in Italy (2017–2030)
Table 25: Total Diagnosed cases of Geographic Atrophy in Italy (2017–2030)
Table 26: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017–2030)
Table 27: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017–2030)
Table 28: Total Treated cases of Geographic Atrophy in Italy (2017–2030)
Table 29: Total Prevalent Cases of Geographic Atrophy in Spain (2017–2030)
Table 30: Total Diagnosed cases of Geographic Atrophy in Spain (2017–2030)
Table 31: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017–2030)
Table 32: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017–2030)
Table 33: Total Treated cases of Geographic Atrophy in Spain (2017–2030)
Table 34: TotalPrevalent Cases of Geographic Atrophy in the United Kingdom (2017–2030)
Table 35: Total Diagnosed cases of Geographic Atrophy in the United Kingdom (2017–2030)
Table 36: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017–2030)
Table 37: Total Geographic Atrophy Cases by Visual Impairment in UK (2017–2030)
Table 38: Total Treated cases of Geographic Atrophy in the UK (2017–2030)
Table 39: Total Prevalent Cases of Geographic Atrophy in Japan(2017–2030)
Table 40: Total Diagnosed cases of Geographic Atrophy in Japan(2017–2030)
Table 41: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017–2030)
Table 42: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017–2030)
Table 43: Total Treated cases of Geographic Atrophy in Japan (2017–2030)
Table 44: Emerging Drugs Key-cross of Geography Atrophy (GA)
Table 45: Pegcetacoplan (APL-2), Clinical Trial Description, 2020
Table 46: Zimura (avacincaptad pegol), Clinical Trial Description, 2020
Table 47: ALK-001, Clinical Trial Description, 2020
Table 48: HMR59 (AAVCAGsCD59), Clinical Trial Description, 2020
Table 49: Risuteganib, Clinical Trial Description, 2020
Table 50: Elamipretide, Clinical Trial Description, 2020
Table 51: GT005, Clinical Trial Description, 2020
Table 52: CPCB-RPE1, Clinical Trial Description, 2020
Table 53: RO7171009; Clinical Trial Description, 2020
Table 54: IONIS-FB-LRx, Clinical Trial Description, 2020
Table 55: OpRegen; Clinical Trial Description, 2020
Table 56: Palucorcel (CNTO 2476); Clinical Trial Description, 2020
Table 57: Clinical Trials of Lampalizumab for GA
Table 58: 7MM Market Size of GA in USD Million (2017–2030)
Table 59: 7MM Market Size of GA by Therapies, in USD Million (2017–2030)
Table 60: United States Market Size of GA, in USD Million (2017–2030)
Table 61: United States Market Size of GA by Therapies, in USD Million (2017–2030)
Table 62: Germany, Market Size of GA, in USD Million (2017–2030)
Table 63: Germany Market Size of GA by Therapies, in USD Million (2017–2030)
Table 64: France, Market Size of GA, in USD Million (2017–2030)
Table 65: France Market Size of GA by Therapies, in USD Million (2017–2030)
Table 66: Italy, Market Size of GA, in USD Million (2017–2030)
Table 67: Italy Market Size of GA by Therapies, in USD Million (2017–2030)
Table 68: Spain, Market Size of GA, in USD Million (2017–2030)
Table 69: Spain Market Size of GA by Therapies, in USD Million (2017–2030)
Table 70: United Kingdom, Market Size of GA, in USD Million (2017–2030)
Table 71: United Kingdom Market Size of GA by Therapies, in USD Million (2017–2030)
Table 72: Japan, Market Size of GA, in USD Million (2017–2030)
List of Figures:
Figure 1: Geographic Atrophy (GA) SWOT Analysis
Figure 2: Dry AMD and Wet AMD
Figure 3: AREDS Risk Factor Scoring System
Figure 4: Stages of AMD
Figure 5: Signs and Symptoms of GA
Figure 6: Risk Factors of GA
Figure 7: Impact of GA progression on patient vision
Figure 8: Pathophysiology of GA
Figure 9: Classical, Lectin, and Alternative Complement Cascade-mediated Pathway
Figure 10: Complement Cascade-mediated Pathway
Figure 11: Assessment of GA
Figure 12: Characteristics of GA across different imaging technique
Figure 13: Progression of GA illustrated with high-resolution SD-OCT over a period of 14 months
Figure 14: Progression of GA illustrated by FAF imaging and GA quantification over time
Figure 15: Semi-automated quantification of GA by means of image analysis software (Region-Finder)
Figure 16: Total Prevalent Cases of Geographic Atrophy in the 7MM (2017–2030)
Figure 17: Total Diagnosed cases of Geographic Atrophy in the 7MM (2017–2030)
Figure 18: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the 7MM (2017–2030)
Figure 19: Total Geographic Atrophy Cases by Visual Impairment in the 7MM (2017–2030)
Figure 20: Treated cases of Geographic Atrophy in the 7MM (2017–2030)
Figure 21: Total Prevalent Cases of Geographic Atrophy in the United States (2017–2030)
Figure 22: Total Diagnosed cases of Geographic Atrophy in the United States(2017–2030)
Figure 23: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United States (2017–2030)
Figure 24: Total Geographic Atrophy Cases by Visual Impairment in the US (2017–2030)
Figure 25: Treated cases of Geographic Atrophy in the United States (2017–2030)
Figure 26: Total Prevalent Cases of Geographic Atrophy in Germany (2017–2030)
Figure 27: Total Diagnosed cases of Geographic Atrophy in Germany (2017–2030)
Figure 28: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Germany(2017–2030)
Figure 29: Total Geographic Atrophy Cases by Visual Impairment in Germany (2017–2030)
Figure 30: Treated cases of Geographic Atrophy in Germany (2017–2030)
Figure 31: Total Prevalent Cases of Geographic Atrophy in France (2017–2030)
Figure 32: Total Diagnosed cases of Geographic Atrophy in France(2017–2030)
Figure 33: Total Diagnosed cases of Geographic Atrophy by Age Distribution in France (2017–2030)
Figure 34: Total Geographic Atrophy Cases by Visual Impairment in France (2017–2030)
Figure 35: Treated cases of Geographic Atrophy in France (2017–2030)
Figure 36: Total Prevalent Cases of Geographic Atrophy in Italy (2017–2030)
Figure 37: Total Diagnosed cases of Geographic Atrophy in Italy (2017–2030)
Figure 38: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Italy (2017–2030)
Figure 39: Total Geographic Atrophy Cases by Visual Impairment in Italy (2017–2030)
Figure 40: Treated cases of Geographic Atrophy in Italy (2017–2030)
Figure 41: Total Prevalent Cases of Geographic Atrophy in Spain (2017–2030)
Figure 42: Total Diagnosed cases of Geographic Atrophy in Spain (2017–2030)
Figure 43: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Spain (2017–2030)
Figure 44: Total Geographic Atrophy Cases by Visual Impairment in Spain (2017–2030)
Figure 45: Treated cases of Geographic Atrophy in Spain (2017–2030)
Figure 46: Total Prevalent Cases of Geographic Atrophy in the United Kingdom (2017–2030)
Figure 47: Total Diagnosed cases of Geographic Atrophy in the United Kingdom(2017–2030)
Figure 48: Total Diagnosed cases of Geographic Atrophy by Age Distribution in the United Kingdom (2017–2030)
Figure 49: Total Geographic Atrophy Cases by Visual Impairment in the UK (2017–2030)
Figure 50: Treated cases of Geographic Atrophy in the United Kingdom (2017–2030)
Figure 51: Total Prevalent Cases of Geographic Atrophy in Japan (2017–2030)
Figure 52: Total Diagnosed cases of Geographic Atrophy in Japan(2017–2030)
Figure 53: Total Diagnosed cases of Geographic Atrophy by Age Distribution in Japan (2017–2030)
Figure 54: Total Geographic Atrophy Cases by Visual Impairment in Japan (2017–2030)
Figure 55: Treated cases of Geographic Atrophy in Japan (2017–2030)
Figure 56: Treatment Algorithm of AMD
Figure 57: Unmet Needs of GA
Figure 58: Factors Which Can Influence Patients Quality of Life (QoL)
Figure 59: Market Size of GA in the 7MM Countries in USD Million (2017–2030)
Figure 60: Market Size of GA by Therapies in the 7MM, in USD Millions (2017–2030)
Figure 61: Market Size of GA in the United States, in USD Millions (2017–2030)
Figure 62: Market Size of GA by Therapies in the United States, in USD Millions (2017–2030)
Figure 63: Market Size of GA in Germany, in USD Millions (2017–2030)
Figure 64: Market Size of GA by Therapies in Germany, in USD Millions (2017–2030)
Figure 65: Market Size of GA in France, in USD Millions (2017–2030)
Figure 66: Market Size of GA by Therapies in France, in USD Millions (2017–2030)
Figure 67: Market Size of GA in Italy, in USD Millions (2017–2030)
Figure 68: Market Size of GA by Therapies in Italy, in USD Millions (2017–2030)
Figure 69: Market Size of GA in Spain, in USD Millions (2017–2030)
Figure 70: Market Size of GA by Therapies in Spain, in USD Millions (2017–2030)
Figure 71: Market Size of GA in the United Kingdom, in USD Millions (2017–2030)
Figure 72: Market Size of GA by Therapies in the United Kingdom, in USD Millions (2017–2030)
Figure 73: Market Size of GA in Japan, in USD Millions (2017–2030)
Figure 74: Market Drivers
Figure 75: Market Barriers
Hemera Biosciences
Alkeus Pharmaceuticals
Iveric Bio (formerly Ophthotech Corporation)
Apellis Pharmaceuticals
